# IL-17A inhibitor
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
About Storm Media
The Storm Media (world.storm.mg) is dedicated to bringing Taiwan's voice to the world. We deliver timely, balanced, and internationally oriented reporting and in-depth analysis on key issues including democratic politics, cross-strait relations, geopolitics, Indo-Pacific strategy, technology industry, and economic trends — helping global readers gain a deeper understanding of Taiwan and the Asia-Pacific region.
About Storm Media
The Storm Media (world.storm.mg) is dedicated to bringing Taiwan's voice to the world. We deliver timely, balanced, and internationally oriented reporting and in-depth analysis on key issues including democratic politics, cross-strait relations, geopolitics, Indo-Pacific strategy, technology industry, and economic trends — helping global readers gain a deeper understanding of Taiwan and the Asia-Pacific region.
Copyright © 2026, Storm Media Group. All rights reserved.
Version: 20261022-081558